PRESS RELEASE: REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)
08 February 2024
REPROCELL will soon add a third clinical pipeline, TIL therapy for cervical cancer, in addition to Stemchymal for spinocerebellar ataxia, and iPSC-derived neuroglial cells for ALS.
Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu
31 January 2024
REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant.
Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives
15 January 2024
SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to globally distribute the high-quality MSCs and MSC derivatives manufactured by Cellcolabs for research and clinical applications. This agreement also includes exclusive distribution in Japan.
End of 2023 Newsletter
15 December 2023
Discover the latest advancements in stem cell and drug discovery research at REPROCELL. From GMP MSC production to Pharmacology-AI services, explore how REPROCELL is revolutionizing the field. Stay updated with their collaborations and partnerships for precision medicine and clinical capabilities.
REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study
24 October 2023
REPROCELL supports Silo Pharma research success, investigating the effects of SPU-21 Peptide on rheumatoid arthritis in a human synovial tissue study
REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs
04 October 2023
Gameto plans to use the iPSC line to advance its program, Fertilo, designed to improve IVF and egg freezing.
Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market
27 September 2023
[Hyderabad, India, 27 September 2023] – Bioserve Biotechnologies (India) Pvt Limited, is teaming up with BioMavericks Ltd., a UK-based company.
Innovation Unleashed: REPROCELL's Q1 Recap and Insights
13 July 2023
REPROCELL had a productive first quarter of 2023-24, launching new services, winning grants, and publishing research. Find out more in our news release.
Vernal Biosciences Announces Partnership With REPROCELL: Exclusive Distributorship in Japan for mRNA and LNP Formulation Services
11 July 2023
Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in Japan at scale for research and clinical applications
Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer
28 June 2023
REPROCELL has entered into a joint research agreement with Keio University regarding the transfer of technology to produce Tumor Infiltrating Lymphocytes (TIL).